Day: August 5, 2025

Events

HSE Grand Rounds to Feature Dr. Stefanie Kennon-McGill

Stefanie Kennon-McGill, Ph.D., Senior Program Manager at BioVentures LLC, will be the featured speaker at 2 p.m. Wednesday, August 27, for the Health Sciences Entrepreneurship Grand Rounds. The topic will be “Leveraging Commercialization to Further Your Impact.” Join us at the Winthrop P. Rockefeller Cancer Institute, 10th Floor, Betsy Blass Conference Room.  The UAMS community and public are welcome to attend.

Read More »
Blog

From Disclosure to Market: How the BioVentures Process Works 

Curious how an idea becomes a protected invention at UAMS?  At BioVentures, we guide innovators through every step, from disclosure to patent decisions and market strategy. Here’s how the process works, what to expect, and how we support you along the way. 1) Submit Your Invention Disclosure  The first step is fully and adequately disclosing your invention to BioVentures by submitting an invention disclosure. Even if you’ve already reached out to schedule a meeting, we require a disclosure to initiate the process. It allows us to review the technology in advance, and gather essential information on compliance, funding, and inventorship.  We’ve recently adopted a new AI-powered disclosure platform to simplify the process. You can upload relevant documents—papers, figures, posters, presentations—and the system will generate a draft disclosure for you to review and edit before submission:  👉 Submit your disclosure  The form captures a complete overview of your invention, its potential applications, and any existing data or prototypes. Once submitted, BioVentures typically reviews the disclosure within 1–2 weeks before scheduling a meeting with you.  Typical timing: BioVentures review in 1–2 weeks.  2) Meeting with the Technology Manager  We meet with the inventor to clarify the technology, confirm federal compliance needs, capture inventor and funding information, and discuss long‑term goals and commercialization paths.  Typical timing: Scheduled within 1–2 weeks after disclosure review.  3) P&CC Decision (Patent & Copyright Committee)  The inventor presents at the P&CC. This committee reviews the presented technology and makes a determination on how the technology should be protected. Outcomes can include:  Typical timing: P&CC is usually scheduled 1–2 months after acceptance of the disclosure.  4) Protection Strategy Based on P&CC Outcome  The legal protection route follows the P&CC decision. If a provisional patent filing is recommended, we move quickly to secure a priority date and a 12‑month window to strengthen data and assess market potential. This is because in the United States is a first to file country which means that the right to a patent generally belongs to whichever inventor files an application with the USPTO first, not to whoever first conceives the idea. As such, protecting your invention in a timely manner is important to us.   Typical timing: Provisional filing is typically completed within a few weeks of the P&CC meeting.  5) Marketing and Commercial Pathways  If the inventor agrees, we begin targeted outreach. Options include:  Why Early Disclosure Matters  Submitting your invention disclosure early is essential. It helps preserve your patent rights before any public disclosure or publication, ensuring your ability to pursue protection. Early disclosure also allows BioVentures to align your IP strategy with funding sources and compliance requirements, and accelerates our ability to evaluate the market potential and identify relevant partners.  This overview is for general information and does not constitute legal advice. Specific strategies and timelines may vary by technology.  Have an invention to disclose? Submit your disclosure now!

Read More »
Blog

BioVentures Supports UAMS M1 Students in PCAR Summer Program

BioVentures supported University of Arkansas for Medical Sciences (UAMS) first-year medical students this summer through the Partnership in Cancer Research (PCAR) program. Over eight weeks, participants worked in multidisciplinary teams to address real-world challenges in cancer prevention, diagnosis, treatment, or survivorship. The program culminated in entrepreneurial pitch presentations to a panel of judges. Three BioVentures team members served as mentors, advising students on refining problem statements, assessing market opportunities, and developing business models. Another team member participated as a judge, providing feedback from a commercialization perspective. The collaboration aimed to foster entrepreneurial thinking, highlight the role of innovation in cancer care, and encourage future clinician-innovators at UAMS. This initiative reflects BioVentures’ ongoing commitment to advancing healthcare entrepreneurship and translating research into real-world impact.

Read More »
News

A New Antibody Detects a Hidden Cancer Signal 

Newly granted patent: U.S. Patent No. 12,281,171 B2, “Periostin Antibodies and Methods of Using the Same” What’s the problem? Some cancers create a unique “signal” by adding a rare sugar modification to proteins like periostin. This tumor-specific marker could help identify and target cancer, but it’s extremely difficult to detect. Traditional tools often miss it because these sugar structures are hard for the immune system to recognize.  What does this technology do? This patent covers a new monoclonal antibody, C9, that targets the sugar marker not the whole protein. Using samples from ovarian cancer patients, inventors at UAMS identified an antibody that binds precisely to this cancer-specific structure. In mouse models, this C9 antibody successfully located and attached to tumors, showing strong potential for cancer imaging and targeted treatment. 

Read More »